1. How Sun Pharma is using share buy back as a tax-efficient tool

How Sun Pharma is using share buy back as a tax-efficient tool

Sun Pharma announced buyback of 7.5 million shares at a price of Rs 900 per share through the tender route with the promoters indicating their intention to participate in the buyback

By: | Updated: June 30, 2016 9:26 AM

Sun Pharma announced buyback of 7.5 million shares at a price of Rs 900 per share through the tender route with the promoters indicating their intention to participate in the buyback. The buyback is valued at Rs 6.75 billion ($100 million). This combination of promoter participation in the buyback and the small size of the buyback itself makes us believe that it is being used as an alternate tax-efficient distribution tool, and is not triggered by “attractive valuations”. Given our view on valuations, we would have been worried had SUNP announced a large buyback (over and above the dividend). However, given the size of the buyback, we believe it is being used as an alternate tool for cash distribution.

Promoters (54.97% shareholding) have indicated their intention of participating in the buyback and given the structure of the buyback (tender offer) and the substantial 20% premium, we do not see the buyback as suggestive of the company finding current valuations attractive.

Also Read: 5 Indian, 1 Chinese firms in race for GAIL project

SUNP has historically paid out 15% dividend with FY16 payout at Rs 7.2 billion. Following this buyback, we see a possibility of reduced annual dividend payout as the company could choose to use a combination of buyback and dividends as a recurring cash distribution policy. We do note that post this buyback, the company cannot announce another buyback for at least 12 months from the closure of the last buyback offer.

  1. No Comments.

Go to Top